Table 4.

T cell analyses at 36 weeks post vaccination

	Ocrelizumab	Natalizumab	Fumarate	Interferon beta	p value
n	10	7a	5b	3b
T cells per sample, mean ± SD	150,639 ± 57,275	234,587 ± 38,830	122,911 ± 82,295	137,531 ± 23,885	0.03
Spike-specific T cells per sample, mean ± SD	943.9 ± 486.2	551.0 ± 237.7	195.8 ± 156.6	174.0 ± 21.1	0.003
Proportion of spike-specific T cells, mean ± SD	0.0065 ± 0.0029	0.0024 ± 0.0012	0.0015 ± 0.0003	0.0013 ± 0.0001	0.0003

Antigen-specific T cells were assessed using T cell receptor (TCR) sequencing (ImmunoSEQT-MAP COVID, Adaptive Biotechnologies) at 36 weeks after the first dose of mRNA-1273. Spike-specific TCR templates were used to compare T cell responses between groups

^aTwo samples were excluded owing to asymptomatic COVID-19

^bThe fumarate and interferon beta groups had fewer T cell samples because additional consent required for T cell testing was not obtained for the excluded participants